Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Co., Inc.

In a report released today, Brendan Lynch from Barclays maintained a Buy rating on Newmark Group, with a price target of $20.00. According to TipRa...

Barclays Sticks to Their Buy Rating for Newmark Group (NMRK)

Insiders have been trading these 5 stocks: (($ET)), (($MRK)), (($LMT)), (($CRWV)) and (($TWLO)). Here is a breakdown of their recent trades and the...

Energy Transfer, Merck, Lockheed, CoreWeave, Twilio Insider Shock

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Hold rating on Merck KGaA, with a price target of €141.00. According t...

Deutsche Bank  Sticks to Its Hold Rating for Merck KGaA (0O14)

Insiders have been trading these 5 stocks: (($COIN)), (($GM)), (($DAL)), (($MRK)) and (($APLD)). Here is a breakdown of their recent trades and the...

Coinbase, GM, Delta, Merck, Applied Digital: Insider Shock

In a report released yesterday, Peter Spengler from DZ BANK AG maintained a Buy rating on Merck KGaA. The company’s shares closed last Thursday at ...

DZ BANK AG Keeps Their Buy Rating on Merck KGaA (0O14)

In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA, with a price target of €150.00. According to TipRanks, W...

Merck KGaA (0O14) Receives a Buy from UBS

Marks Electrical Group Plc ( ($GB:MRK) ) has issued an update. Marks Electrical Group reported that shareholders approved all 13 resolutions at its...

Marks Electrical Wins Strong Shareholder Backing at 2026 AGM

Jefferies analyst James Vane maintained a Hold rating on Merck KGaA today and set a price target of €129.00. According to TipRanks, Vane is ranked ...

Merck KGaA (0O14) Gets a Hold from Jefferies

Berenberg Bank analyst Luisa Hector maintained a Hold rating on Merck & Company yesterday and set a price target of $127.00. The company’s shares c...

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

Exchange-traded funds (ETFs) are a preferred investment choice, as they help investors mitigate risk through diversification at low costs. Moreover...

3 Best ETFs to Invest In, According to the AI Analyst – 8/5/2026

RBC Capital analyst Trung Huynh reiterated a Buy rating on Merck & Company yesterday and set a price target of $142.00. The company’s shares closed...

Merck & Company (MRK) Gets a Buy from RBC Capital

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Merck & Company, with a price target of $150.00. According to ...

Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)

Dividend ETFs are one of the most popular ways to earn passive income, but choosing the right fund isn’t always easy. Among the leading options are...

SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?

There’s a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on Newmark Group (NMRK) and Regency Centers (REG) with...

Analysts Are Bullish on These Real Estate Stocks: Newmark Group (NMRK), Regency Centers (REG)

Barclays analyst Emily Field maintained a Buy rating on Merck & Company today and set a price target of $150.00. According to TipRanks, Field is a ...

Merck & Company (MRK) Receives a Buy from Barclays

Jefferies analyst James Vane maintained a Hold rating on Merck KGaA today and set a price target of €129.00. According to TipRanks, Vane is an anal...

Merck KGaA (0O14) Receives a Hold from Jefferies

Dividend ETFs remain a go-to choice for investors seeking steady income. Two leading choices are the Schwab U.S. Dividend Equity ETF ($SCHD) and th...

VYMI vs. SCHD: Which Is the Best Dividend ETF for Passive Income?

Deutsche Bank analyst Falko Friedrichs maintained a Hold rating on Merck KGaA today and set a price target of €125.00. According to TipRanks, Fried...

Deutsche Bank  Remains a Hold on Merck KGaA (0O14)

Investors prefer exchange-traded funds (ETFs) for their ability to generate attractive returns while lowering risk through diversification. There a...

Best ETFs to Invest In, According to AI Analyst, 7/22/2026

UBS analyst Matthew Weston maintained a Buy rating on Merck KGaA today and set a price target of €150.00. According to TipRanks, Weston is a 4-star...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$135.97	+0.10%	8.46M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$135.97	+0.1%	8.46M
3
4
5
6

MRK

Get Merck & Co., Inc. Data in Excel

Get Merck & Co., Inc. Data in Excel